Jeevan [for Wes]'s questions to Pacira Biosciences Inc (PCRX) leadership • Q1 2025
Question
Jeevan from Truist Securities asked if there were any enhancements for EXPAREL in development that could extend its life cycle or expand its label.
Answer
CEO Frank Lee responded that the company continues to innovate around EXPAREL, evidenced by the recent 18th patent listed in the Orange Book, with more expected. However, he clarified that while some studies are ongoing, there are no new plans for additional clinical indications for EXPAREL at this time.